Science Corp. reports its first Stargardt disease patient using the PRIMA retinal implant
A man with the inherited eye disease received the chip in Sydney in May and has begun reading letters and a word in rehabilitation, the company says.
Science Corp. says the first person with Stargardt disease has received its PRIMA retinal implant. CEO Max Hodak announced the case at TechCrunch Disrupt on October 13. The man was implanted in May at Sydney Eye Hospital in Australia as part of an ongoing trial of PRIMA in inherited retinal diseases. According to the company, he recognized a letter in his first rehabilitation session and read a word in his second. The 2 mm chip sits at the back of the eye and receives images from camera glasses; the vision it gives is black and white and limited to a few letters at a time.
PRIMA is already sold in Europe for geographic atrophy from macular degeneration. This is a single patient and an early company report, not trial results.
Learn more: Visual prosthesis · Science Corp.